Literature DB >> 29930027

Complete Sequences of the Human T-Cell Leukemia Virus Type 1 Proviral Genomes from Newly Established Adult T-Cell Leukemia Cell Lines in Oita Prefecture, Japan.

Takuro Fukumoto1, Emi Ikebe1,2, Masao Ogata3, Kazuhiro Kohno3, Madoka Kuramitsu2, Yusuke Sato1, Nichole Fife1, Takashi Matsumoto1, Takaaki Yahiro1, Masanori Ikeda4, Shuichi Kusano4, Akihiko Okayama5, Mitsuo Hori6, Naoki Hijiya7, Yoshiyuki Tsukamoto7, Yuka Hirashita7, Masatsugu Moriyama7, Kamruddin Ahmed8, Hiroo Hasegawa9, Akira Nishizono1, Masumichi Saito10, Hidekatsu Iha11.   

Abstract

We report two complete proviral genome sequences of human T-cell leukemia virus type 1 (HTLV-1) isolated from the peripheral blood specimens of acute type adult T-cell leukemia (ATL) patients in Oita Prefecture, Japan.
Copyright © 2018 Fukumoto et al.

Entities:  

Year:  2018        PMID: 29930027      PMCID: PMC6013615          DOI: 10.1128/genomeA.00090-18

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus belonging to the family Retroviridae, genus Deltaretrovirus, and an etiological agent for adult T-cell leukemia (ATL) (1) and neurological disorders termed HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) (2). Current studies indicate that there are more than 20 million HTLV-1 carriers worldwide, and 5% of these carriers will develop ATL (3). HTLV-1 produces two oncogenic proteins, Tax and HBZ. While Tax is essential for initial immortalization of HTLV-1-infected cells, HBZ is more important for the onset of ATL symptoms through its immune compromising and cellular proliferating function. Messenger RNAs of both oncoproteins are transcribed from the 3ʹ regions of HTLV-1 provirus genome where each open reading frame is located in either the sense or antisense part (4). The expression of Tax is frequently canceled by deletion (5) or epigenetic modulation (i.e., methylation) (6) of the proviral 5ʹ regions. It is widely recognized that Tax is less important for ATL onset, and a previous report indicated Tax’s disappearance in the freshly isolated HTLV-1-positive peripheral blood cells (PBLs) from 60% of ATL cases (6). Here, we report the complete HTLV-1 provirus genome sequence of OATL9, a novel HTLV-1/EBV-infected B-cell line isolated from the acute type ATL patient (7). The study was approved through the institutional review board of the Oita University Faculty of Medicine, approval number 267. Two provirus clones within OATL9 were located in chromosomes 1 and 15, respectively, and amplified by a PCR method that has been described (8). The amplicons were purified using the PCR cleanup gel extraction kit (Macherey-Nagel) and sequenced directly by an ABI 3730XL sequencer using BigDye Terminator (Applied Biosystems). The sequence data were assembled into contiguous sequences using the software ATGC (Genetyx, Tokyo, Japan), and sequence alignments with the consensus sequence of accession number AB513134 were generated by a progressive pairwise global alignment method using the same software. It remains to be elucidated how Tax and HBZ contribute to the viral tumorigenesis or how the integration site of the virus affects its gene expression property. We are conducting molecular biological analysis on this cell line to elucidate its mechanistic properties for hematologic immortalization ability.

Accession number(s).

The genome sequences of these HTLV-1 proviral genomes have been deposited in GenBank under accession numbers LC183873 (for OATL9A, located in chromosome 1) and LC378575 (for OATL9B, located in chromosome 15).
  8 in total

1.  Proviral Features of Human T Cell Leukemia Virus Type 1 in Carriers with Indeterminate Western Blot Analysis Results.

Authors:  Madoka Kuramitsu; Tsuyoshi Sekizuka; Tadanori Yamochi; Sanaz Firouzi; Tomoo Sato; Kazumi Umeki; Daisuke Sasaki; Hiroo Hasegawa; Ryuji Kubota; Rieko Sobata; Chieko Matsumoto; Noriaki Kaneko; Haruka Momose; Kumiko Araki; Masumichi Saito; Kisato Nosaka; Atae Utsunomiya; Ki-Ryang Koh; Masao Ogata; Kaoru Uchimaru; Masako Iwanaga; Yasuko Sagara; Yoshihisa Yamano; Akihiko Okayama; Kiyonori Miura; Masahiro Satake; Shigeru Saito; Kazuo Itabashi; Kazunari Yamaguchi; Makoto Kuroda; Toshiki Watanabe; Kazu Okuma; Isao Hamaguchi
Journal:  J Clin Microbiol       Date:  2017-07-12       Impact factor: 5.948

2.  Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia.

Authors:  S Tamiya; M Matsuoka; K Etoh; T Watanabe; S Kamihira; K Yamaguchi; K Takatsuki
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

3.  HTLV-I associated myelopathy, a new clinical entity.

Authors:  M Osame; K Usuku; S Izumo; N Ijichi; H Amitani; A Igata; M Matsumoto; M Tara
Journal:  Lancet       Date:  1986-05-03       Impact factor: 79.321

4.  Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease.

Authors:  M Yoshida; I Miyoshi; Y Hinuma
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

5.  Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells.

Authors:  Satoshi Takeda; Michiyuki Maeda; Shigeru Morikawa; Yuko Taniguchi; Jun-Ichirou Yasunaga; Kisato Nosaka; Yuetsu Tanaka; Masao Matsuoka
Journal:  Int J Cancer       Date:  2004-04-20       Impact factor: 7.396

Review 6.  Human T-cell leukemia virus type 1: replication, proliferation and propagation by Tax and HTLV-1 bZIP factor.

Authors:  Masao Matsuoka; Jun-ichirou Yasunaga
Journal:  Curr Opin Virol       Date:  2013-09-21       Impact factor: 7.090

7.  Epidemiological Aspects and World Distribution of HTLV-1 Infection.

Authors:  Antoine Gessain; Olivier Cassar
Journal:  Front Microbiol       Date:  2012-11-15       Impact factor: 5.640

8.  Oral administration of an HSP90 inhibitor, 17-DMAG, intervenes tumor-cell infiltration into multiple organs and improves survival period for ATL model mice.

Authors:  E Ikebe; A Kawaguchi; K Tezuka; S Taguchi; S Hirose; T Matsumoto; T Mitsui; K Senba; A Nishizono; M Hori; H Hasegawa; Y Yamada; T Ueno; Y Tanaka; H Sawa; W Hall; Y Minami; K T Jeang; M Ogata; K Morishita; H Hasegawa; J Fujisawa; H Iha
Journal:  Blood Cancer J       Date:  2013-08-16       Impact factor: 11.037

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.